Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc repurchased 405,500 ordinary shares on 15 October 2025 as part of its existing buyback programme, executed by BNP Paribas SA under a non-discretionary agreement announced on 30 September 2025. The shares were bought at a volume-weighted average price of 1,617.97p, within a price range of 1,608.00p to 1,633.00p, and will be held as treasury shares.
Since 30 September 2025, the company has purchased 3,919,500 ordinary shares. Following this transaction, GSK holds 251,384,344 ordinary shares in treasury and has 4,064,029,485 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,064,029,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc filed a Form 6-K reporting transaction notifications. The filing lists share transactions with an ISIN GB00BN7SWP63 at a price of 3.0300 and multiple entries for ISIN US37733W2044 at a price of $40.7387. The document repeats the US ISIN and price across several lines and provides an aggregated section header, but it does not disclose volumes, the parties to the transactions, transaction types, or any explanatory context. The filing is dated September 22, 2025.
GSK plc reported share repurchases under its ongoing buyback programme. On 18 September 2025 the Company, through Merrill Lynch International, purchased 15,858 ordinary shares at prices between 1,471.00p and 1,480.00p, with an aggregated per-share reference of 1,476.54p. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 29,330,461 ordinary shares. After these transactions GSK holds 247,464,844 shares in treasury and has 4,067,938,124 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,067,938,124 and the percentage of voting rights attributable to treasury shares is stated as 6.08%.
GSK plc repurchased 209,886 ordinary shares on 17 September 2025 through Merrill Lynch International under its ongoing buyback programme, at prices ranging from 1,461.50p to 1,478.50p, with an average price reported as 1,471.87p. The purchased shares will be held as treasury shares.
Since the non-discretionary agreement with the broker on 4 June 2025 the company has acquired 29,314,603 ordinary shares. After this trade GSK holds 247,448,986 shares in treasury and has 4,067,953,982 ordinary shares in issue (excluding treasury), representing total voting rights of 4,067,953,982 and 6.08% of voting rights attributable to treasury shares.
GSK announced a five-year, $30 billion investment plan in the United States to expand research, development and supply chain infrastructure. The announcement includes a $1.2 billion package for advanced manufacturing, AI and digital capabilities that will create hundreds of highly skilled U.S. jobs and build a next-generation biologics "flex" factory at Upper Merion, Pennsylvania, with construction planned to begin in 2026. GSK said the wider $30 billion commitment will fund capital projects across its U.S. supply chain, boost R&D drug discovery and clinical trial activity, and increase the U.S. share of its global clinical studies. The filing notes GSK has added roughly $2 billion in U.S. manufacturing investments over the last 12 months, including an $800 million Marietta, Pennsylvania facility started in October 2024, and that its global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year.
GSK plc announced that, acting through Merrill Lynch International, it repurchased 210,377 ordinary shares on 16 September 2025 at prices between 1,462.00p and 1,478.00p per share, with an aggregated average shown as 1,468.98p. These shares will be held as treasury stock as part of the buyback programme announced 4 June 2025. Since 4 June 2025 the company has repurchased 29,104,717 ordinary shares. After this trade GSK holds 247,239,100 shares in treasury and has 4,068,163,868 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,163,868 and treasury-held voting rights of 6.08%.
GSK plc reported a purchase of ordinary shares under its ongoing buyback programme. On 15 September 2025 the Company, acting through Merrill Lynch International, purchased 253,331 ordinary shares at prices ranging up to 1,505.50p, with an aggregated weighted lowest/highest/average price line reported as 1,476.00p / 1,505.50p / 1,482.92p on that date. Since the non-discretionary agreement with the Broker dated 4 June 2025, GSK has purchased 28,894,340 ordinary shares in total. Following the 15 September purchase the Company holds 247,028,723 shares in treasury and has 4,068,374,245 ordinary shares in issue (excluding treasury), giving total voting rights of 4,068,374,245 and treasury shares representing 6.07% of voting rights.
GSK plc reports on 12 September 2025 that, acting through Merrill Lynch International, it purchased 203,447 ordinary shares at an average price of 1,512.69p per share as part of its ongoing buyback programme under a non-discretionary broker agreement dated 4 June 2025. Since 4 June 2025 the company has repurchased 28,641,009 ordinary shares. Following the transaction GSK will hold 246,775,392 shares in treasury and will have 4,068,627,576 ordinary shares in issue (excluding treasury). Total voting rights are 4,068,627,576 and treasury shares represent 6.07% of voting rights.
GSK plc reported purchases of its ordinary shares on 11 September 2025 under an existing buyback programme. Acting through Merrill Lynch International, the Company purchased 205,355 ordinary shares at prices ranging from 1,494.50p to 1,518.50p, resulting in an average price shown as 1,509.04p for the aggregated trade line. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since 4 June 2025 the Company has acquired 28,437,562 ordinary shares under the programme. After this transaction GSK will hold 246,571,945 shares in treasury and have 4,068,829,782 ordinary shares in issue (excluding treasury), with total voting rights of 4,068,829,782 and 6.06% of voting rights attributable to treasury shares.
GSK plc reports a share repurchase carried out on 10 September 2025 under its ongoing buyback programme executed by Merrill Lynch International. On that date the Company purchased 213,147 ordinary shares at prices ranging between 1,480.50p and 1,500.00p per share; the aggregated lowest and highest prices reported are 1,480.50p and 1,500.00p respectively.
Since the non-discretionary agreement with the Broker on 4 June 2025, GSK has bought 28,232,207 ordinary shares. Following the latest purchases the Company holds 246,366,590 treasury shares and has 4,069,035,137 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,069,035,137 and treasury-held voting rights of 6.05%.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
